ArticleAmerican health & drug benefits2015
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
Article in American health & drug benefits, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04979546 (Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis: A Randomized Trial
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Maintaining Mobility and Balance in Multiple Sclerosis: A Systematic Review Examining Potential Impact of Symptomatic Pharmacotherapy.CNS drugs · 2025Pooled it
- The effect of nurse practitioner (NP-led) care on health-related quality of life in people with multiple sclerosis - a randomized trial.BMC neurology · 2022Trial
- Review
- Astroglial connexin 43 is a novel therapeutic target for chronic multiple sclerosis model.Scientific reports · 2024Article
- Evaluating the impact of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a study protocol for a randomized controlled trial.BMC neurology · 2023Article
- The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective.Therapeutic advances in neurological disorders · 2020Review
- Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population.Neurology and therapy · 2019Article
- Healthcare resources utilisation in primary progressive multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Article
- Therapies for mobility disability in persons with multiple sclerosis.Expert review of neurotherapeutics · 2018Review
- Needs of Persons with Neurological Disorders.Indian journal of psychiatric social work · 2018Article
- Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis.Degenerative neurological and neuromuscular disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significant innovations in the treatment of patients with multiple sclerosis (MS) have primarily addressed the frequency of flare-ups in relapsing-remitting MS (RRMS). Many advances have been made in this area, and the medical community may be on the verge of a serious discussion of what constitutes a truly effective MS treatment. Certainly, it is important to further delay MS flare-ups and more effectively treat RRMS symptoms. However, great strides in reducing or preventing MS-related disability and providing neuroprotection have been elusive. Many unmet needs are still voiced by patients with MS, clinicians, and caregivers. Current information on the need for progress in various areas is reviewed in this article, including psychosocial care, treatments for progressive MS, biomarker identification, functional outcome measures, individualization of treatment, reducing side effects of medications, and improving medication adherence.
Indexed as
Identifiers
26702334PMC4684633W2184060246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.